| Previous COVID-19 infection and antibody levels after vaccination H Ali, B Alahmad, AA Al-Shammari, A Alterki, M Hammad, P Cherian, ... Frontiers in public health 9, 778243, 2021 | 99 | 2021 |
| Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis M Shehab, F Alrashed, S Shuaibi, D Alajmi, A Barkun BMJ open gastroenterology 8 (1), e000571, 2021 | 67 | 2021 |
| Exploring the pipeline of novel therapies for inflammatory bowel disease; state of the art review Y Zurba, B Gros, M Shehab Biomedicines 11 (3), 747, 2023 | 30 | 2023 |
| Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease: systematic review and network meta-analysis of randomized … M Shehab, F Alrashed, V Heron, S Restellini, T Bessissow Inflammatory Bowel Diseases 29 (3), 367-375, 2023 | 27 | 2023 |
| Serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with inflammatory bowel disease on biologic therapies M Shehab, F Alrashed, A Alfadhli, K Alotaibi, A Alsahli, H Mohammad, ... Vaccines 9 (12), 1471, 2021 | 24 | 2021 |
| Immunogenicity of BNT162b2 vaccine in patients with inflammatory bowel disease on infliximab combination therapy: a multicenter prospective study M Shehab, M Abu-Farha, F Alrashed, A Alfadhli, K Alotaibi, A Alsahli, ... Journal of clinical medicine 10 (22), 5362, 2021 | 18 | 2021 |
| Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis F Alrashed, R Battat, I Abdullah, A Charabaty, M Shehab BMJ Open Gastroenterology 8 (1), e000774, 2021 | 16 | 2021 |
| Effectiveness of inspectors' team in increasing compliance with personal protective equipment use and reducing COVID19 infection spread among healthcare workers M Shehab, S Shuaibi, I Qadhi, A Alfadhli Infection Prevention in Practice 3 (2), 100137, 2021 | 14 | 2021 |
| COVID-19 vaccine hesitancy among patients with inflammatory bowel disease receiving biologic therapies in Kuwait: a cross-sectional study M Shehab, Y Zurba, A Al Abdulsalam, A Alfadhli, S Elouali Vaccines 10 (1), 55, 2021 | 12 | 2021 |
| Tofacitinib for a child with refractory steroid-dependent ulcerative colitis: a case report and review of the literature R Alajmi, M Alabdulhadi, AA Alali, M Shehab The American Journal of Case Reports 22, e934460-1, 2021 | 12 | 2021 |
| Relationship between patient sex and serum tumor necrosis factor antagonist drug and anti-drug antibody concentrations in inflammatory bowel disease; a nationwide cohort study M Shehab, H Alasfour, I Abdullah, G Alhendi, A Alhadab, A Alfadhli, ... Frontiers in Medicine 8, 801532, 2021 | 11 | 2021 |
| Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta … M Shehab, F Alrashed, A Alkazemi, PL Lakatos, T Bessissow Expert Review of Gastroenterology & Hepatology 17 (5), 469-477, 2023 | 8 | 2023 |
| Upadacitinib as a rescue therapy in acute severe ulcerative colitis: a case report and review of the literature NM Ali, MA Shehab The American Journal of Case Reports 24, e940966-1, 2023 | 8 | 2023 |
| Histological disease activity as predictor of clinical relapse, hospitalization, and surgery in inflammatory bowel disease: systematic review and meta-analysis M Shehab, S Al Akram, A Hassan, F Alrashed, V Jairath, T Bessissow Inflammatory Bowel Diseases 30 (4), 563-572, 2024 | 7 | 2024 |
| The Role of Clinical Pharmacists in Improving Quality of Care in Patients with Inflammatory Bowel Disease: An Evaluation of Patients’ and Physicians’ Satisfaction F Alrashed, N Almutairi, M Shehab Healthcare 10 (10), 1818, 2022 | 5 | 2022 |
| Impact of biologics and small molecules for inflammatory bowel disease on COVID19related hospitalization and mortality: A systematic review and metaanalysis F Alrashed, H Alasfour, M Shehab JGH Open 6 (4), 241-250, 2022 | 5 | 2022 |
| Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory … F Alrashed, I Abdullah, A Alfadhli, M Shehab Frontiers in Pharmacology 14, 1243080, 2023 | 4 | 2023 |
| Biologic therapies for the treatment of post-ileal pouch anal anastomosis surgery chronic inflammatory disorders: systematic review and meta-analysis M Shehab, F Alrashed, A Charabaty, T Bessissow Journal of the Canadian Association of Gastroenterology 5 (6), 287-296, 2022 | 4 | 2022 |
| COVID-19 vaccine booster dose willingness among patients with inflammatory bowel disease on Infliximab and Vedolizumab: a cross-sectional study M Shehab, F Alrashed, A Alfadhli Vaccines 10 (8), 1166, 2022 | 4 | 2022 |
| Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective … M Shehab, F Alrashed, M Alyaseen, Z Safar, T Adekunle, A Alfadhli, ... Vaccines 12 (4), 364, 2024 | 1 | 2024 |
